Principal Investigators

    CATALANO, SUSAN M

    Institution

    COGNITION THERAPEUTICS, INC.

    Contact information of lead PI

    Country

    USA

    Title of project or programme

    Phase 1b first-in-patient safety trial for CT1812, a novel Alzheimer’s synaptic protection therapeutic

    Source of funding information

    NIH (NIA)

    Total sum awarded (Euro)

    € 2,211,622.94

    Start date of award

    15/08/2016

    Total duration of award in years

    1

    The project/programme is most relevant to:

    Alzheimer's disease & other dementias

    Keywords

    Acquired Cognitive Impairment... Aging... Alzheimer's Disease... Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD)... Brain Disorders... Clinical Research... Clinical Research - Extramural... Clinical Trials and Supportive Activities... Dementia... Neurodegenerative... Neurosciences... Patient Safety... Translational Research

    Research Abstract

    Abstract – Project Summary Cognition Therapeutics Inc. (CogRx) has discovered CT1812, a novel oligomer receptor antagonist that is the only drug candidate demonstrated to prevent and displace binding of Abeta oligomers to receptors on brain cells. By stopping the initiating event in the Abeta oligomer cascade, this first-in–class drug candidate completely blocks downstream synaptotoxicity and restores memory to normal in aged transgenic mouse models of Alzheimer’s disease. CT1812 is an orally administered lipophilic isoindoline formulated as a fumarate salt that is rapidly absorbed and highly brain penetrant. It displaces receptor-bound Abeta oligomers by allosterically antagonizing the sigma-2/PGRMC1 receptor (Izzo et al., 2014a, b). CT1812 thus represents the first disease-modifying therapeutic that will test the oligomer hypothesis of Alzheimer’s disease. Such a drug candidate would significantly impact the lives of the 35 million patients worldwide suffering from AD and MCI, for whom no disease-modifying treatment exists. This application proposes to assess the safety and pharmacokinetics of oral doses of CT1812 in a Phase Ib clinical trial in early Alzheimer’s patients. Successful completion of this Phase Ib safety trial will lay the groundwork for future studies of CT1812’s therapeutic effectiveness in larger Phase 2 trials in Alzheimer’s patients.

    Lay Summary

    Project Narrative Cognition Therapeutics Inc. has discovered a drug candidate that promises to stop and even reverse the memory loss in Alzheimer’s disease. This drug candidate, CT1812, works by a completely novel mechanism to stop the binding of toxic proteins that build up in the brains of Alzheimer’s patients known as Abeta oligomers. We are requesting funding support to conducct clinical trials of this drug candidate in Alzheimer’s patients in order to measure its safety. Such a drug candidate would significantly impact the lives of the 35 million patients worldwide suffering from Alzheimer’s disease and Mild Cognitive Impairment, for whom no disease-modifying treatment exists.

    Further information available at:

Types: Investments > €500k
Member States: United States of America
Diseases: Alzheimer's disease & other dementias
Years: 2016
Database Categories: N/A
Database Tags: N/A

Export as PDF